Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program from GT Apeiron, taking control of the promising compound GTAEXS617 (‘617) along with all associated intellectual property. Under the terms of the agreement, Exscientia will pay GT Apeiron $10 million […]
Enveda Biosciences, a leader in utilizing artificial intelligence (AI) to convert nature’s chemistry into groundbreaking medicines, has successfully raised an additional $55 million. This funding round is an addition to a previously raised $119 million combined in Series B and B1, bringing significant new investors on board, including Premji Invest, Lingotto Investment Fund, Microsoft, and […]
In a significant stride toward revolutionizing drug discovery and development, Seoul-based biotech firm Oncocross announced on May 22nd a renewed joint research agreement with JW Pharmaceutical. This collaboration aims to leverage artificial intelligence to accelerate the development of new drugs, particularly in the fields of anticancer and regenerative medicine. Leveraging AI for Faster, More Efficient […]
Accenture (NYSE: ACN) has announced a strategic investment through Accenture Ventures into Turbine, a pioneering predictive simulation company. This investment aims to enhance Turbine’s capabilities in delivering profound biological insights to global biopharma companies, thereby accelerating key drug development processes. Revolutionizing Drug Discovery with AI Turbine’s proprietary technology, the Simulated Cell platform, harnesses machine learning […]